“Bringing the world into focus
through the lens of Scripture”









K-House Africa


Banking Details



 Africa news





The Rise Of Islam












Global Government
















 Kings High Way Briefing Packs







 In The News provided by Koinonia House

Monitor The Strategic Trends

Biotech & Global Pestilence Introduction:


The threat of germ warfare has brought to the forefront long-forgotten diseases like plague, anthrax, and smallpox. Recent television news programs have highlighted secret projects in the former Soviet Union to develop antibiotic-resistant strains of genetically engineered viruses and bacteria.





Human Nature


Ron Matsen





About available formats


What does it mean to be human? Philosophers, theologians, sociologists and psychologists have attempted to understand the nature of mankind for ages. Their conclusions often contradict each other which lead to confusion rather than clarification. Clearly Man is a very complicated social being. The Bible tells us that man is “fearfully and wonderfully made.”
  • How do we understand our makeup and does it make a difference?
  • What is the meaning of being “created in the image of God?”
  • What causes our natural responses and can we change this behaviour?

Join Ron Matsen from the Executive Briefing Room of the River Lodge, New Zealand as he explores the subject of our “Human Nature” and gives insight into the architecture and accountability of all mankind.

This briefing pack contains approx. 2 hours of teaching.

  • DVD discs
  • M4A files
  • PDF Notes file

CANCER  Awareness



Dedicated Page




Price R 179





Beginning of Wisdom



 Dr. Chuck Missler

“The fear of God is the beginning of wisdom.” Proverbs 9:10

But how do we balance the awesome majesty due to the Creator and Ruler of the universe with the gracious family intimacy that is now available to us through the completed work of Christ?

What does His Holiness demand of us, personally?

What are the hazards of failing to render the Almighty His due, while availing ourselves the riches committed to us of the precious promises in His Word?

How do we deal with these paramount issues facing us daily in practical challenges?

Chuck Missler grapples with these wildly misunderstood tensions with down-to-earth frankness and Biblically-based candor.




Price R 179.00



The Gospel: The Message of Reconciliation


by Ron Matsen 




Price R 179.00





One of the last instructions given by Jesus to the Church was, “Go into all the world and preach the gospel.” (Mark 16:15)

The fact is most Christians don’t know how to share their faith effectively. Sadly, many of the people they know in the world today are wandering around, lost and without hope, having never heard the wonderful Message of Reconciliation.

How would you answer the question, “What must I do to be saved?”

What are the essential facts, demands and promises of the Gospel?

Why are we told to evangelize?

Join Ron Matsen in the Executive Briefing Room of the River Lodge, New Zealand as he explores the subject of “The Gospel – The Message of Reconciliation” and gives practical insight into how to share the essential doctrines of salvation.

This briefing pack contains 2 hours of teaching

© Copyright 2013




Disaster Management News from TerraDaily.com


Earth News, Earth Science, Energy Technology, Environment News















Price R599.00





·         Dr. Chuck Missler - The seven Myths of Eschatology, How to Avoid Deception, Know Your Calling.

·         Dr. Steve Elwart - What is the World Coming To? A Global Intelligence Update. 

·         Chris Corlett - On Education: Playgrounds, Politics and Parents.

·         Gary Stearman - New Insights on the Last Generation, Abraham and the Four Kings.

·         Joel Richardson - The Rise of Antichrist, Encouragement for the Last Days.

·         Dr. William Welty - The Validity of the State of Israel.

·         Chris Putnam - Astrobiology: The 'Science' With Nothing To Study, Who are the Immortals Driving Paranormal Paradigm Shift?

·         David McAlvany - A Legacy of Debt, International Families: Your Family Legacy From Finish to Start. 

·         Bob Cornuke - Traditions,Temples and Beyond, Alternate Location of the Crucifixion.

·         Joseph Farah - Restoration vs. the Spirit of Diotrephes.

·         Ron Matsen - Finding Peace in the Face of Peril. 

·         Lt. Col. Robert Maginnis, US Army (retired) - Never Submit.





Behold a Livid Horse: Emergent Diseases and Biochemical Warfare



PRICE R 249.00




Behold a Livid Horse:

 Emergent Diseases


Biochemical Warfare




by Dr. Chuck Missler



Dr. Chuck Missler explores these and other questions below concerning this climactic Fourth Horsemen and the unique role it plays in the End-Time Scenario:

•Why are previously conquered diseases now making a comeback?

•How real is the threat of biological terrorism?

•Why is it more dangerous than chemical terrorism?

•Was the AIDS virus deliberately designed? By whom? And why?

•Is there any truth behind an agenda to control (and reduce) the world’s population? By whom? And why?

•Who are the two riders associated with the Livid Horse? How do they differ?


This briefing pack contains 2 hours of teaching


Available in the following formats



•2 MP3 files

•1 PDF Notes file

•Colour, Full screen 16:9, Dolby Digital 2.0 stereo,



Diseases/Conditions News Headlines - Yahoo! News



Chronic sleep deprivation tied to more depression for young women

‎Friday, ‎May ‎27, ‎2016, ‏‎10:18:48 PMGo to full article
By Kathryn Doyle (Reuters Health) - One night of short sleep may lead to less depression the following day, but chronic short sleep is tied to greater depression overall for young women, according to a new study. “The overall message that poor quality and insufficient sleep lead to poor mood, which, in turn, worsens sleep was not surprising,” said lead author David A. Kalmbach of the University of Michigan Medical School in Ann Arbor. The researchers studied 171 female college students for two weeks, beginning with an in-person questionnaire assessment of anxiety and depression levels and continuing with daily self-reported measures of mood and anxiety.

People with celiac disease advised to consider pneumonia vaccine

‎Friday, ‎May ‎27, ‎2016, ‏‎5:57:43 PMGo to full article
By Madeline Kennedy (Reuters Health) – Seniors are advised to get vaccinated against pneumonia, but that precaution is also a good idea for people of any age with celiac disease, according to a U.K. study. Despite their greater risk for pneumonia, only about one quarter of celiac patients get a pneumonia vaccine after they are diagnosed, the study team writes in the journal Alimentary Pharmacology and Therapeutics. To assess the link between pneumonia and celiac disease, the researchers used data on English patients collected between 1997 and 2011, including 9,803 with celiac disease and a comparison group of 101,755 people without celiac.

Roche boosted by early trial success with blood cancer drug

‎Friday, ‎May ‎27, ‎2016, ‏‎1:56:23 PMGo to full article
Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustrationBy Silke Koltrowitz and Ben Hirschler ZURICH/LONDON (Reuters) - Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful, lifting prospects for a medicine that will be pivotal as the Swiss company fights the threat of biosimilar competition. Investors had anticipated results of the study in 2017 but Roche was able to prove a clear benefit at the interim stage, implying the drug had a strong effect. The company is holding back detailed results until an upcoming medical meeting but it said Gazyva proved significantly better than its older drug Rituxan at delaying disease progression in people with previously untreated follicular lymphoma.

EU regulator's advisory panel backs AstraZeneca diabetes drug

‎Friday, ‎May ‎27, ‎2016, ‏‎1:44:13 PMGo to full article
Former Chelsea manager Jose Mourinho leaves his house in London(Reuters) - A panel that advises the European drugs regulator has supported an approval for AstraZeneca Plc's diabetes drug combination. The European Medicines Agency said on Friday that the Committee for Medicinal Products for Human Use backed AstraZeneca's combination of saxagliptin and dapagliflozin. The components of the combination are currently sold separately for the treatment of type 2 diabetes under the Onglyza and Farxiga brand names.

Bird flu reappears in Cameroon, killing thousands of birds

‎Thursday, ‎May ‎26, ‎2016, ‏‎5:20:17 PMGo to full article
YAOUNDE, Cameroon (AP) — Cameroon's government says that the H5N1 strain of the bird flu virus has reappeared in Cameroon after an 8-year absence.

Girls’ early puberty and breast development tied to depression

‎Thursday, ‎May ‎26, ‎2016, ‏‎5:01:45 PMGo to full article
By Lisa Rapaport (Reuters Health) - Girls who go through puberty and develop breasts earlier than peers may have a higher risk of depression as well, a Chinese study suggests. Researchers analyzed data on puberty timing and adolescent depression for almost 5,800 children born in Hong Kong in 1997. For boys, the timing of genital development was unrelated to the presence of depression, researchers report in the journal Pediatrics.

Financial crisis may have caused 500,000 cancer deaths worldwide: study

‎Thursday, ‎May ‎26, ‎2016, ‏‎1:20:33 AMGo to full article
An additional 500,000 people worldwide may have died of cancer from 2008-2010, locked out of treatment by unemployment and health care cuts caused by the financial crisis, a healthcare study says on May 25, 2016The global financial crisis may have caused an additional 500,000 cancer deaths from 2008-2010, a new study said Thursday, with patients locked out of treatment because of unemployment and healthcare cuts. The figures were extrapolated from an observed rise in cancer deaths for every percentage increase in unemployment, and every drop in public healthcare spending. "From our analysis we estimate that the economic crisis was associated with over 260,000 excess cancer deaths in the OECD (34-member Organisation for Economic Cooperation and Development) alone, between 2008-2010," study author Mahiben Maruthappu of Imperial College London told AFP.

U.S. panel backs approval of Sanofi combination diabetes drug

‎Thursday, ‎May ‎26, ‎2016, ‏‎12:16:19 AMGo to full article
French multinational pharmaceutical company SANOFI logo is seen at the headquarters in ParisOne day after recommending approval of a new diabetes drug made by Novo Nordisk A/S, a U.S. advisory panel on Wednesday recommended approval of a similar product made by Sanofi SA. The panel voted 12-2, with one person not voting, that the Food and Drug Administration should approve Sanofi's combination drug, iGlarLixi, for patients with type 2 diabetes. The agency is not obliged to follow the advice of its advisory panels but typically does so.

Congress: Support, Don't Stymie, Student Health and Nutrition

‎Wednesday, ‎May ‎25, ‎2016, ‏‎10:37:29 PMGo to full article
Congress: Support, Don't Stymie, Student Health and NutritionApproximately every six years, the federal government goes through a major reevaluation and reauthorization of its child nutrition laws. And so this year we are looking to Congress and the president to pass legislation that will help schools determine and achieve their wellness goals and preserve and enhance students' access to nutritious...

Lung cancer patients at bigger cancer centers may have better outcomes

‎Wednesday, ‎May ‎25, ‎2016, ‏‎9:30:27 PMGo to full article
By Kathryn Doyle (Reuters Health) - Lung cancer patients getting radiation at hospitals with higher rates of participation in a clinical trial fared significantly better compared to those at centers with low participation, U.S. researchers say. Using trial participation as a proxy for the volume of cancer patients a hospital treats, the study found an overall 10 percent difference in survival rates, and that patients at centers with higher participation also had better disease management and fewer adverse events. “It’s hard to say conclusively but the underlying hypothesis and belief is that at large volume centers, where physicians and care team are specialized in treating that specific type of malignancy, particularly in instances where treatment is life saving or the risk for severe toxicity is high, that outcomes are better at high volume centers, as opposed to small community centers where the people there treat a variety of things,” said lead author Dr. Bree R. Eaton of Winship Cancer Institute of Emory University in Atlanta.

After skin cancer, sun protection is still spotty

‎Wednesday, ‎May ‎25, ‎2016, ‏‎7:05:15 PMGo to full article
By Lisa Rapaport (Reuters Health) - Even though people may be more careful in the sun after skin cancer, having had a malignancy still doesn’t convince everybody to take basic precautions like wearing hats or sunscreen, a recent U.S. study suggests. Researchers analyzed survey data from about 760 adults with a history of skin cancer and more than 34,000 people without prior malignancies. With a skin cancer history, people were more than twice as likely to wear sunscreen and more than 50 percent more likely to wear hats and long sleeves than individuals who didn’t have a history of these tumors, the study found.

Lung Cancer in Adolescents: A Grim Inheritance?

‎Wednesday, ‎May ‎25, ‎2016, ‏‎4:27:25 PMGo to full article
Another Big Mistake in North CarolinaWhether you're bemoaning the annoying cowlick that came from your father or flashing the perfect smile your mother passed along, what the mirror reminds all of us is that we're each the unique sum of our genetic parts. And while we've always known that those traits indelibly link us to our ancestry, what we're only beginning to understand is...

Drug discovery brings hope of new breast cancer treatments

‎Wednesday, ‎May ‎25, ‎2016, ‏‎10:36:18 AMGo to full article
The new drug could have fewer side effects for patients.Scientists from the University of Edinburgh, Scotland, have identified a new drug that could offer an effective future therapy for breast cancer. While a potential treatment is still a long way off, this discovery could give rise to promising clinical trials. The potentially life-changing compound for women suffering from breast cancer is called eCF506.

Uptick in colon cancer rates among people under 50

‎Wednesday, ‎May ‎25, ‎2016, ‏‎9:21:40 AMGo to full article
Uptick in colon cancer rates among people under 50Colon cancer among people under 50 is on the rise, and tumors are often diagnosed at an advanced stage, according to research presented Tuesday. "While the healthcare system has done a great deal to address colorectal cancer in people over 50 -- heightening patient awareness and increasing screenings -- our findings show that much more needs to be done to fight this cancer in people under 50, a group not normally considered at risk," said lead author Elie Sutton, a research fellow at Mt. Sinai West Hospital in New York. "Not only did we find that the rate of colorectal cancer in this group is rising, we also saw that within the group that was diagnosed at a younger age, a higher percentage were diagnosed at later stages of cancer (stage three or four), which is very concerning," she added.

FDA panel recommends approval of Novo Nordisk diabetes drug

‎Wednesday, ‎May ‎25, ‎2016, ‏‎8:25:10 AMGo to full article
A U.S. advisory panel on Tuesday recommended approval of a new diabetes drug made by Novo Nordisk A/S that combines two of its existing treatments in a fixed-dose combination designed to be both effective and convenient. The panel voted 16-0 that the Food and Drug Administration should approve the drug, iDegLira, for patients with type 2 diabetes. The FDA is not obliged to follow the advice of its advisory panels but typically does so.

Biden to host national cancer research summit in Washington

‎Wednesday, ‎May ‎25, ‎2016, ‏‎12:18:15 AMGo to full article
In this May 20, 2016, file photo, Vice President Joe Biden listens as President Barack Obama speaks to members of the media in the Oval Office at the White House in Washington Biden will bring together scientists, oncologists, donors and patients for a national conference on cancer research in Washington, the White House said May 24. Dubbed the “National Cancer Moonshot Summit,” the summit is scheduled for June 29 at Howard University, and the White House said it planned to organize dozens regional summits on the same day in communities far from the capital. (AP Photo/Andrew Harnik)WASHINGTON (AP) — Vice President Joe Biden will bring together scientists, oncologists, donors and patients for a national conference on cancer research in Washington, the White House said Tuesday.

Consider obesity surgery more often for diabetes: Guidelines

‎Tuesday, ‎May ‎24, ‎2016, ‏‎9:36:48 PMGo to full article
Graphic explains two common types of weight-loss surgery; 2c x 2 1/2 inches; 96.3 mm x 63 mm;WASHINGTON (AP) — New guidelines say weight-loss surgery should become a more routine treatment option for diabetes, even for some patients who are mildly obese.

Call for gastric surgery to be standard diabetes treatment

‎Tuesday, ‎May ‎24, ‎2016, ‏‎6:58:44 PMGo to full article
A person receives a test for diabetes during Care Harbor LA free medical clinic in Los AngelesBy Kate Kelland LONDON (Reuters) - People with diabetes should be offered gastric surgery as a standard treatment option which could help control it for years without medication, the world's leading diabetes groups said. A joint statement from a 45-strong group said on Tuesday that bariatric, or metabolic, surgery could have a significant benefit for hundreds of thousands of patients worldwide, which they said represented one of the biggest shifts in diabetes treatment guidelines since the advent of insulin. The new guidelines say surgery to reduce the stomach and induce weight loss should be recommended to treat all diabetes patients whose body mass index (BMI) is 40 or over, regardless of their blood glucose control, as well as those with a BMI of 30 and over whose blood sugar levels are not being controlled by lifestyle changes or medication.

UCB faces U.S. patent challenge for epilepsy drug

‎Tuesday, ‎May ‎24, ‎2016, ‏‎12:37:19 PMGo to full article
The logo of Belgian drug, chemical, and plastics group UCB is seen at the entrance of the company's headquarters in BrusselsThe U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals. U.S. pharmaceuticals group Argentum Pharmaceuticals, which challenged UCB's patent, said in a statement late on Monday that the PTO had granted approval for a review of the sole remaining U.S. patent of UCB's Vimpat drug, due to expire in March 2022. The PTO had concluded that Argentum had established a "reasonable likelihood that it would prevail" in showing that certain claims made by UCB in the patent are "unpatentable", Argentum said, adding a decision was likely within a year.

Loss of Y chromosome linked to Alzheimer's disease: study

‎Tuesday, ‎May ‎24, ‎2016, ‏‎10:18:13 AMGo to full article
Loss of Y chromosome linked to Alzheimer's disease: studyAbout one in five men over age 80 lose the Y chromosome from their blood cells, and this condition has now been linked to an increased risk of Alzheimer's disease, researchers said Monday. The condition known a loss of Y, or LOY, is the most common genetic mutation acquired during a man's lifetime. Previous research has shown LOY can raise the likelihood of cancer and is more frequently found in smokers.

No More Lives Lost: Now Is the Time to Fix America’s Mental Health System

‎Monday, ‎May ‎23, ‎2016, ‏‎10:41:09 PMGo to full article
No More Lives Lost: Now Is the Time to Fix America’s Mental Health SystemMay is Mental Health Month, a time to reaffirm our nation’s commitment to increasing our understanding of mental illness, improving access to treatment, and letting those who are affected by mental illnesses know they are not alone. This month provides us with the opportunity to continue our national conversation about the mental health system, yet now is also the time that we must turn that dialogue into action. Today, one in five Americans have a mental health condition.

Depression and Me

‎Monday, ‎May ‎23, ‎2016, ‏‎7:07:28 PMGo to full article
Depression and MeI have always been very vocal about how I lost my mother to suicide four years ago. I have been vocal about her struggle with mental illness, more specifically depression and anxiety. I saw the depression transform my mother into someone who raised me, loved me and held me into someone I no longer recognized. Something I haven't been as vocal...

FDA staff question usefulness of Sanofi diabetes drugs

‎Monday, ‎May ‎23, ‎2016, ‏‎7:06:28 PMGo to full article
A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver SpringA preliminary review by the U.S. Food and Drug Administration questioned the usefulness of a combination diabetes drug made by Sanofi SA's and said it was unclear whether one component, lixisenatide, contributed to its benefit. The French drugmaker is seeking approval for lixisenatide alone and as part of a combination product, iGlarLixi, which Sanofi hopes will establish a new paradigm for diabetes therapy by treating patients earlier and more aggressively. The review comes ahead of a Wednesday meeting of an FDA advisory panel that will discuss lixisenatide and the combination treatment, iGlarLixi, an injection which delivers lixisenatide and Sanofi's drug Lantus in a fixed-dose combination.

Young female cancer survivors not clear on infertility risks

‎Monday, ‎May ‎23, ‎2016, ‏‎6:05:45 PMGo to full article
By Lisa Rapaport (Reuters Health) - Many young women who survive cancer don’t understand how tumor treatments affect their reproductive health even though the therapy can trigger infertility, a survey suggests. Researchers focused on 346 women who were around 30 years old on average and had typically finished cancer treatment about five years earlier. At the time participants completed the survey, 106 women said they had been told they would not be able to become pregnant or carry a baby to term as a result of their cancer treatment, and 21 women said they had taken steps to preserve fertility before treatment such as egg or embryo freezing.

Mental Health: Where Nutrition Meets Psychiatry

‎Monday, ‎May ‎23, ‎2016, ‏‎4:54:44 PMGo to full article
Another Big Mistake in North Carolina"Mental disorders -- major depression and anxiety in particular -- have been described as an impending global epidemic." -- Nutritional psychiatry research: an emerging discipline and its intersection with global urbanization, environmental challenges, and the evolutionary mismatch.Research from the emerging field of nutritional psychiatry...

Green hopes as Australia legalises medical cannabis

‎Sunday, ‎May ‎22, ‎2016, ‏‎9:53:22 AMGo to full article
Support for the legalisation of cannabis has grown in Australia in recent years, with 91% in favour of it for the seriously ill, according to a 2015 pollJai Whitelaw was 10 when he first took medical cannabis, given to him by his mother in a bid to treat the debilitating epilepsy that saw him endure up to 500 seizures a day. Faced with the stark choice of breaking the law in the hope of soothing his chronic pain, or denying him possible relief, Michelle Whitelaw reached breaking point. Now, almost two years on, things are set to change as Australia brings in new laws allowing the drug to be used for medical purposes.

Makeover coming for food nutrition labels

‎Friday, ‎May ‎20, ‎2016, ‏‎11:10:15 PMGo to full article
First lady Michelle Obama announces a makeover for food nutrition labels with calories listed in bigger, bolder type and a new line for added sugars, while speaking to the Building a Healthier Future Summit in Washington, Friday, May 20, 2016. (AP Photo/Jacquelyn Martin)WASHINGTON (AP) — A new look is coming to Nutrition Facts labels on food packages, with more attention to calorie counts and added sugars. And no longer will a small bag of chips count as two or three servings.

Skin cancer patients face deadly risk using ‘black salve’ home remedy

‎Friday, ‎May ‎20, ‎2016, ‏‎4:46:06 PMGo to full article
By Madeline Kennedy (Reuters Health) – People who fear they have skin cancer, or know it, and decide to try an unapproved product called “black salve” may face infection, scarring and worse cancer outcomes, doctors warn. Utah researchers surveyed black salve users and found that most did not talk to a doctor before trying the product - which is on a U.S. Food and Drug Administration list of “fake ‘cancer cures’ consumers should avoid” - nor were they aware of its harmful effects. Black salve refers to products containing zinc chloride and sanguinarine, both corrosive ingredients that can severely damage skin, the study team writes in the Journal of the American Academy of Dermatology.

FDA staff question utility, trials of Novo Nordisk diabetes drug

‎Friday, ‎May ‎20, ‎2016, ‏‎4:09:00 PMGo to full article
Employees stand in the insulin production plant of Danish multinational pharmaceutical company Novo Nordisk in ChartresA preliminary review by the U.S. Food and Drug Administration of Novo Nordisk A/S's experimental diabetes drug, IDegLira, questioned the interpretability of the study findings and practical use of the treatment, according to a review posted on the agency's website on Friday. The review comes ahead of a May 24 meeting of an FDA advisory panel that will discuss the drug and make recommendations as to whether it should be approved. The FDA is not obliged to follow the advice of its advisory panels but typically does.

Depression symptoms may improve with cochlear implants

‎Friday, ‎May ‎20, ‎2016, ‏‎3:23:25 PMGo to full article
A speech and hearing impaired child with a cochlear implant which he received free of charge attends a therapy session at the Pradera hospital in HavanaBy Kathryn Doyle (Reuters Health) – For older adults with severe hearing loss, receiving a cochlear implant may help to lift depression symptoms, a small U.S. study suggests. “Hearing loss has long been understood to be a factor that could likely contribute to depressive symptoms in adults,” said senior author Dr. Frank R. Lin of the Center on Aging and Health at Johns Hopkins Medical Institutions in Baltimore. “In our study, patients who were receiving cochlear implants (and who had more severe hearing losses to begin with) had worse depressive scores at baseline than those getting hearing aids,” Lin told Reuters Health by email.

A healthier lifestyle could cut deaths from cancer by up to half finds new US study

‎Friday, ‎May ‎20, ‎2016, ‏‎12:39:42 PMGo to full article
A healthier lifestyle could cut deaths from cancer by up to half finds new US studyA new large-scale US study has found that many cancer cases and deaths in individuals could be prevented by following a healthy lifestyle. The team of researchers, from Massachusetts General Hospital, Harvard Medical School and the Harvard T.H. Chan School of Public Health, looked at data from two study groups of white participants to examine the possible associations between a "healthy lifestyle pattern" and the rate of cancer cases and deaths from the disease -- the leading cause of death in the United States. 16,531 women and 11,731 met all four of the healthy lifestyle criteria and were considered to be at a low risk from cancer.

Roche breast cancer drug Perjeta rejected by UK cost agency

‎Friday, ‎May ‎20, ‎2016, ‏‎1:07:26 AMGo to full article
File photo of Roche tablets positioned in front of a displayed Roche logoRoche's breast cancer drug Perjeta, or pertuzumab, has been turned down for use on Britain's state health service, making it the latest in a number of pricey new cancer treatments deemed not to offer value for money. The National Institute for Health and Care Excellence (NICE) said in draft guidance on Friday that it could not recommend the drug as a good use of NHS resources because of uncertainties about its long-term benefits. Perjeta is designed for use in combination with chemotherapy and Roche's older drug Herceptin, or trastuzumab, before breast cancer surgery to shrink the cancer so that it becomes operable.

EU delays vote on weed-killer glyphosate licence amid cancer row

‎Thursday, ‎May ‎19, ‎2016, ‏‎6:06:10 PMGo to full article
Weedkillers including Monsanto's Roundup are displayed for sale at a garden shop at Bonneuil-Sur-MarneBy Alissa de Carbonnel BERLIN/BRUSSELS (Reuters) - The European Union on Thursday delayed a vote on renewing sales approval for the pesticide glyphosate, used in Monsanto's weed-killer Roundup, amid a transatlantic row over whether it may cause cancer. Without those two countries' support, the European Commission lacks the majority it needs for a binding vote: "Since it was obvious that no qualified majority would have been reached, a vote was not held," a Commission spokeswoman said. The EU executive had hoped for a decision to stop the clock ticking on a six-month phase-out period for glyphosate products when the existing authorisation lapses at the end of June.

Lung cancer breathalyzer in UK clinical trials

‎Thursday, ‎May ‎19, ‎2016, ‏‎1:40:33 PMGo to full article
By Matthew Stock A breathalyzer designed to detect the early signs of lung cancer is undergoing clinical trials at 17 British hospitals, with the aim of having the non-invasive technology in clinics in 2017.    Cambridge-based Owlstone Medical has developed a microchip sensor technology to measure the volatile organic compounds (VOCs) in patients' exhaled breath.

In Yemen's war, untreated cancer patients wait for death

‎Thursday, ‎May ‎19, ‎2016, ‏‎9:34:21 AMGo to full article
This image made from video taken on May 7, 2016 shows, Feras Ali Hassan, a 10-year-old who is being diagnosed with leukemia, left, and his father Ali Hassan, waiting in front of a clinic in Taiz. Yemen's civil war has wreaked massive destruction and created a humanitarian disaster in what was already the Arab's world's poorest country. Taiz, one of the worst battlegrounds, has seen another level of misery: The city of around 400,000 is home to Yemen's largest cancer hospital, the Amal Hospital, and the war has doomed hundreds of its patients to death because they are unable to get treatment. Hassan, was diagnosed with leukemia at the age of 6, had seen improvement over two and a half years of treatment at Amal. But for months, his father couldn't get him to treatment because the family lived in a frontline district, Wadi Hanish. (AP Video via AP)TAIZ, Yemen (AP) — When Ali Ghanem's doctors told him his cancer had spread from his colon to his backbone, they said they didn't have the facilities to give him the needed radiation treatment in his home city of Taiz, in central Yemen, and that he needed to get to the capital.

China, India face huge mental health burden: study

‎Thursday, ‎May ‎19, ‎2016, ‏‎1:03:55 AMGo to full article
There are more people in China and India coping with mental, neurological and substance use problems than in all high-income countries combined, research has foundChina and India are home to more than a third of people with mental illness, but only a tiny fraction of them receive medical help, according to studies released Wednesday. China, meanwhile, will struggle with the rapid rise of dementia in its greying population, a by-product in part of strict birth control policies put in place more than 35 years ago. Neither country is adequately equipped to deal with their mental health needs, according the trio of reports, published in medical journal The Lancet and The Lancet Psychiatry to mark the launch of the China-India Mental Health Alliance.

German Merck, Pfizer immunotherapy shows promise in rare skin cancer

‎Thursday, ‎May ‎19, ‎2016, ‏‎12:25:28 AMGo to full article
The logo of German pharmaceuticals company Merck is seen at the company's headquarters in DarmstadtGermany's Merck KGaA on Wednesday reported encouraging interim data against a rare and aggressive form of skin cancer from a mid-stage trial of its experimental drug that helps the immune system attack tumors. In the 61-patient study, about 30 percent of those with Merkel skin cell carcinoma treated with Merck's avelumab saw their tumors shrink or disappear. Avelumab, which German Merck is developing with Pfizer Inc , belongs to a class of drugs called PD-L1 inhibitors that block a mechanism tumors use to hide from the immune system, allowing it to recognize and attack the cancer.

Immune drug for deadly skin cancer shows long-term survival

‎Thursday, ‎May ‎19, ‎2016, ‏‎12:22:11 AMGo to full article
This 2015 photo made available by Merck shows the drug Keytruda. A study released Wednesday, May 18, 2016 shows the new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years. (Michael Lund/Merck via AP)CHICAGO (AP) — A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. It's a remarkable advance for patients who until recently faced dismal chances of living for more than a few months.

How To Have More Inclusive Conversations Regarding Mental Health

‎Wednesday, ‎May ‎18, ‎2016, ‏‎11:12:56 PMGo to full article
How To Have More Inclusive Conversations Regarding Mental HealthA considerable number of college students struggle with mental health-related issues such as anxiety, depression, post-traumatic stress disorder, and eating disorders, among others. It is encouraging to see the growing dialogue and resources surrounding mental health on campuses; however, conversation surrounding mental health can be unevenly...

Precision medicine approach to cancer improves on older methods: study

‎Wednesday, ‎May ‎18, ‎2016, ‏‎11:05:50 PMGo to full article
By Julie Steenhuysen CHICAGO (Reuters) - Precision medicine, or the practice of targeting biological markers on a patient's tumors, proved significantly more effective at shrinking tumors and stalling the progression of cancer in the first large-scale analysis of such treatments. The precision medicine approach is part of a transition away from treating cancer based on specific organs. Instead, it focuses on the defective genes driving the disease, and uses that information to determine which drugs, or combinations of drugs, could best attack specific biological targets on tumors.

Pfizer cancer drug shows promise in combo with Merck's Keytruda

‎Wednesday, ‎May ‎18, ‎2016, ‏‎11:04:53 PMGo to full article
A company logo is seen at a Pfizer office in DublinAn experimental Pfizer drug that helps the immune system fight cancer showed early promise against a variety of cancers when used with Merck & Co's immunotherapy Keytruda in a small clinical trial, according to data released on Wednesday. The first wave of successful cancer immunotherapies, such as Keytruda, block mechanisms that tumors use to evade the immune system. Pfizer's utomilumab, which targets an antibody known as 4-1BB, stimulates a more intense immune system attack.

Pfizer's Ibrance delays breast cancer progression -study

‎Wednesday, ‎May ‎18, ‎2016, ‏‎11:03:25 PMGo to full article
The Pfizer logo is seen at their world headquarters in New YorkPfizer Inc's Ibrance in combination with another commonly-used drug kept advanced breast cancer in check significantly longer than the standard treatment alone in a late stage study, according to data released on Wednesday. Some 28,000 women in the United States have received Ibrance therapy since the accelerated approval, Pfizer said. A confirmatory trial called Paloma-2 studied the treatment with letrozole, which reduces estrogen production, in 666 post-menopausal women.

U.S. FDA approves Roche's immunotherapy for bladder cancer

‎Wednesday, ‎May ‎18, ‎2016, ‏‎10:53:31 PMGo to full article
File of the logo of the Swiss drugmaker Roche is seen on a factory in BurgdorfRoche Holding AG won earlier-than-expected U.S. approval on Wednesday for its bladder cancer drug Tecentriq, the company's first entry in a new class of cancer drugs that work by harnessing the body's own immune system. Tecentriq is the first new drug to treat patients with the most common form of bladder cancer approved by the U.S. Food and Drug Administration in 30 years, and the first in a class known as PD-L1 inhibitors which help prevent cancer cells from evading the immune system. PD-L1 drugs and their close cousins, PD1-inhibitors, are considered one of the most promising areas of cancer research.

Women and Arthritis: Stephanie Aleite

‎Wednesday, ‎May ‎18, ‎2016, ‏‎10:44:08 PMGo to full article
About 1.3 million people in the U.S. live with rheumatoid arthritis (RA), a serious autoimmune disease that occurs when your immune system mistakenly starts attacking healthy joints. The true struggle of living with autoimmune disease is known to people experiencing the pain daily and to family members and caregivers. Among them is Miami...

Women and Arthritis: Kathleen Turner

‎Wednesday, ‎May ‎18, ‎2016, ‏‎10:41:45 PMGo to full article
The verdict of doctors sounded like a death sentence: in the near future Hollywood star, 80's sex symbol, Kathleen Turner was expected to spend the rest of her life in a wheelchair. At the peak of her acting career the Oscar and two-time Golden Globe winner, Kathleen Turner, was diagnosed with rheumatoid arthritis. While on-set, actress almost...

5 Things They Never Tell You About Life After Cancer

‎Wednesday, ‎May ‎18, ‎2016, ‏‎8:24:45 PMGo to full article
5 Things They Never Tell You About Life After CancerThere will be a plethora of resources to help you cope during treatment, but life after cancer has it's own battles. Because though treatment ends, but cancer never truly leaves you...At 17, I fought an advanced form of cancer at a world renowned hospital. I was given every form of support and educational resource possible, from counselors to...

Deal still possible in Colombia-Novartis cancer drug talks : minister

‎Wednesday, ‎May ‎18, ‎2016, ‏‎5:13:43 PMGo to full article
A Novartis logo is pictured on its headquarters building in MumbaiBy Julia Symmes Cobb and Luis Jaime Acosta BOGOTA (Reuters) - The door remains open for Swiss pharmaceutical company Novartis to reach a deal with Colombia to lower the cost of cancer drug imatinib and prevent the Andean country from allowing generic production of the medication, the health minister said. Colombia asked Novartis to lower the price of imatinib, which is used to treat leukemia and other cancers, in an effort to save costs for the country's beleaguered healthcare system but negotiations broke down and prompted the country to announce it may declare a compulsory license. Compulsory licenses permit companies to make cheaper generic versions of medications considered vital to public health, overriding drugs patents.

Oramed says oral insulin succeeds in midstage type 2 diabetes trial

‎Wednesday, ‎May ‎18, ‎2016, ‏‎1:37:39 PMGo to full article
Nadav Kidron, CEO of Oramed Pharmaceuticals, poses for a photo in JerusalemTiny Israeli drugmaker Oramed Pharmaceuticals Inc on Wednesday said its experimental oral insulin succeeded in significantly reducing night-time blood glucose in patients with type 2 diabetes, according to initial data from a midstage trial. Oramed uses a protective coating and a high-enough dose of insulin so that most of it can be destroyed and still deliver a clinically beneficial amount of the hormone. "It's been a long trip but it's finally at the point that it's beyond a doubt, the oral insulin works," Nadav Kidron, chief executive of Jerusalem-based Oramed, said in a telephone interview.

Novartis breast cancer drug set to take on Pfizer's Ibrance

‎Wednesday, ‎May ‎18, ‎2016, ‏‎11:01:36 AMGo to full article
The logo of Swiss pharmaceutical company Novartis is seen on its headquarters building in Basel(Reuters) - A clinical trial testing an experimental breast cancer pill from Novartis has been stopped early because of good results, boosting the Swiss company's efforts to build up its oncology business. The news puts Novartis on track to compete with a similar blockbuster product from Pfizer that is already on the market. Novartis said on Wednesday that testing of LEE011 in combination with letrozole in the late-stage study had been halted early after it met its goal of significantly extending the time patients lived without their disease progressing.

AstraZeneca's Lynparza fails in gastric cancer combination test

‎Wednesday, ‎May ‎18, ‎2016, ‏‎8:29:55 AMGo to full article
The logo of AstraZeneca is seen on a medication package in a pharmacy in LondonLONDON (Reuters) - AstraZeneca's recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday. The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings. ...




Weathering the Coming Storm




Price R399.00





Dr. Chuck Missler, an internationally known business executive, outlines our current economic predicament and defensive steps you can take to lessen the impact of the impending economic crisis. As a Bible teacher for over 30 years with a ministry reaching over 40 countries, Chuck shares some key strategies to prepare yourself spiritually and practically.

Is the World facing another major economic upheaval?

What is the best strategy to protect your family in times of economic uncertainty?

The Church has enjoyed a relatively peaceful existence in the West for a few centuries but the with the coming persecution, how do we go about organizing home study and home-church?

Soul Survival – Keeping your “lamp full” during the hard times ahead.

Join Dr. Chuck Missler and Ron Matsen in the Executive Brie fing Room of
The River Lodge, New Zealand, in an intensive summary outlining what lies
ahead and how we can prepare for the coming storm.

Runtime: Approx. 5 hours

© 2012 Koinonia House Inc.

Available in the following formats:



•3 Disks
•5 M4A Files
•1 PDF Notes File
•Color, 16:9, Dolby Digital 2.0 stereo, Region encoding (This DVD will be viewable in other countries WITH the proper DVD player and television set.)



 of the




Dr. Chuck Missler and Ron Matsen


Price R 499.00


There are many diverse anticipations concerning the Coming World Leader, commonly referred to as “The Antichrist.” This study will explore the Biblical descriptions with the specific expectations of the globalists, Islam, the Vatican, Freemasonry, and others.
• Will he be a Nephilim?
• Why is the Vatican openly preparing to receive an “alien” visitor?
• Will he be a resurrection of Nimrod? Is his DNA a factor?
• What are the expectations of transhumanist technologists in this regard?
Clearly, the Bible has much more to illuminate this issue far beyond the popular conceptions; and yet the composite perspective will astonish most. Furthermore, is there a climactic cosmic deception being prepared that, if it were possible, “it would deceive the very elect”? Jesus commanded us, “Be not deceived.” But, how?
How close are these events to our current horizon?
Join Dr. Chuck Missler and Ron Matsen in an intensive summary of some of the Strategic Trends that will impact all of us.
Available in the following formats:

•3 Discs
•6 M4A Files
•1 PDF Notes File
•Color, Fullscreen 16:9, Dolby Digital 2.0 stereo, Region  encoding ( This DVD will be viewable in other countries WITH the proper DVD player and television set.)




Feed image

Featured Video

End the Shame. End the Isolation. End Fistula.







Genetically Modified Food & People.




 Angels, Volume III:

The Denizens of the Metacosm





Price R 179.00


Angels, Volume III: The Denizens of the Metacosm



by Dr. Chuck Missler



Volumes 1 & 2 of this series explored the finite limits and boundaries of our physical reality. After probing the limits of both the Macrocosm and the Microcosm, we discovered that our reality is but a shadow of larger reality, the Metacosm, a domain of extra-dimensional transfers and other paradoxical phenomena.


Volume 3 explores the contradictory behavior of UFOs and other demonic deceptions characteristic of the End Times. Explore these topics in more detail in either this two-hour briefing, Angels Vol 3: The Denizens of the Metacosm or our six-hour extensive study, Expectations of the Antichrist.



• Are they real?

• Why do UFOs enjoy a military classification higher than our most sensitive weapons systems?

• Why are the events which occurred in Roswell New Mexico still classified after 66 years?

• Why is the Vatican openly preparing to receive an Alien Visitor?

• How should a Christian deal with the occurrences of Alien abductions?

• Jesus admonished us to “Be not deceived.” How?

• How do we prepare for the deception which, “if it were possible, would deceive the very elect”?


Join Dr. Chuck Missler in the Executive Briefing Room of the River Lodge, New Zealand, exploring the misinformation, (and deliberate disinformation) about the various “denizens of the Metacosm” and other insights of the invisible war unfolding on our near horizon.


This briefing pack contains 2 hours of teaching


Available in the following formats



•1 Disc

•2 M4A Files

•Color, Fullscreen 16:9, Dolby Digital 2.0 stereo, Region. This DVD will be viewable in other countries WITH the proper DVD player and television set.)



PRICE  R 159.00


PRICE R 159.00



Price  R 159.00



Price R 159.00













Global Events Disaster Site

Extreme Weather, Epidemic, Terror Attack, Biological Hazard,

Volcano Eruption, Earthquake, Incidents at Sea



"In seasons of severe trial, the Christian has nothing on earth that he can trust to, and is therefore compelled to cast himself on God alone. When no human deliverance can avail, he must simply and entirely trust himself to the providence and care of God. Happy storm that wrecks a man on such a rock as this! O blessed hurricane that drives the soul to God--and God alone!"
- Spurgeon





+27 11 969 0086


















Featured Commentaries

Learn the Bible

 in 24 hours

Old Testament






Joshua and The Twelve Tribes


Ruth and Esther

I and II Samuel

I and II Kings

I and II Chronicles

Ezra & Nehemiah





Song of Songs







Joel and Amos

Jonah, Nahum & Obadiah



The Minor



New Testament







I & II Corinthians




Colossians and Philemon

I and II






I and II Peter

I, II, and III John